Watanabe Toshiaki, Muro Kei, Ajioka Yoichi, Hashiguchi Yojiro, Ito Yoshinori, Saito Yutaka, Hamaguchi Tetsuya, Ishida Hideyuki, Ishiguro Megumi, Ishihara Soichiro, Kanemitsu Yukihide, Kawano Hiroshi, Kinugasa Yusuke, Kokudo Norihiro, Murofushi Keiko, Nakajima Takako, Oka Shiro, Sakai Yoshiharu, Tsuji Akihito, Uehara Keisuke, Ueno Hideki, Yamazaki Kentaro, Yoshida Masahiro, Yoshino Takayuki, Boku Narikazu, Fujimori Takahiro, Itabashi Michio, Koinuma Nobuo, Morita Takayuki, Nishimura Genichi, Sakata Yuh, Shimada Yasuhiro, Takahashi Keiichi, Tanaka Shinji, Tsuruta Osamu, Yamaguchi Toshiharu, Yamaguchi Naohiko, Tanaka Toshiaki, Kotake Kenjiro, Sugihara Kenichi
Department of Surgical Oncology, The Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan.
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Int J Clin Oncol. 2018 Feb;23(1):1-34. doi: 10.1007/s10147-017-1101-6. Epub 2017 Mar 27.
Japanese mortality due to colorectal cancer is on the rise, surpassing 49,000 in 2015. Many new treatment methods have been developed during recent decades. The Japanese Society for Cancer of the Colon and Rectum Guidelines 2016 for the treatment of colorectal cancer (JSCCR Guidelines 2016) were prepared to show standard treatment strategies for colorectal cancer, to eliminate disparities among institutions in terms of treatment, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding between health-care professionals and patients by making these Guidelines available to the general public. These Guidelines were prepared by consensus reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches, and in view of the medical health insurance system and actual clinical practice settings in Japan. Therefore, these Guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. As a result of the discussions held by the Guideline Committee, controversial issues were selected as Clinical Questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here we present the English version of the JSCCR Guidelines 2016.
日本因结直肠癌导致的死亡率呈上升趋势,2015年超过49,000人。近几十年来开发了许多新的治疗方法。日本结直肠癌学会2016年结直肠癌治疗指南(JSCCR指南2016)旨在展示结直肠癌的标准治疗策略,消除各机构在治疗方面的差异,消除不必要的治疗和治疗不足的情况,并通过向公众提供这些指南来加深医护人员与患者之间的相互理解。这些指南是由JSCCR指南委员会通过共识制定的,基于对文献检索所获证据的仔细审查,并考虑到日本的医疗保险制度和实际临床实践情况。因此,这些指南可作为实际临床实践中治疗结直肠癌的工具。更具体地说,它们可作为从患者处获得知情同意以及为每位患者选择治疗方法的指南。由于指南委员会进行的讨论,有争议的问题被选为临床问题并给出了建议。每项建议都附有证据分类以及基于指南委员会成员达成的共识的推荐类别分类。在此我们呈现JSCCR指南2016的英文版本。